+
データを開く
-
基本情報
登録情報 | データベース: PDB / ID: 8j6f | ||||||
---|---|---|---|---|---|---|---|
タイトル | Cryo-EM structure of the Tocilizumab Fab/IL-6R complex | ||||||
![]() |
| ||||||
![]() | IMMUNE SYSTEM / antibody / IL-6R / structural protein | ||||||
機能・相同性 | ![]() ciliary neurotrophic factor binding / hepatic immune response / interleukin-6 receptor activity / interleukin-6 binding / ciliary neurotrophic factor-mediated signaling pathway / interleukin-11 receptor activity / interleukin-11 binding / ciliary neurotrophic factor receptor complex / interleukin-6 receptor complex / T-helper 17 cell lineage commitment ...ciliary neurotrophic factor binding / hepatic immune response / interleukin-6 receptor activity / interleukin-6 binding / ciliary neurotrophic factor-mediated signaling pathway / interleukin-11 receptor activity / interleukin-11 binding / ciliary neurotrophic factor receptor complex / interleukin-6 receptor complex / T-helper 17 cell lineage commitment / negative regulation of collagen biosynthetic process / endocrine pancreas development / vascular endothelial growth factor production / negative regulation of interleukin-8 production / positive regulation of glomerular mesangial cell proliferation / positive regulation of leukocyte chemotaxis / neutrophil mediated immunity / cell surface receptor signaling pathway via STAT / cytokine receptor activity / Interleukin-6 signaling / MAPK3 (ERK1) activation / interleukin-6-mediated signaling pathway / MAPK1 (ERK2) activation / monocyte chemotaxis / positive regulation of osteoblast differentiation / positive regulation of chemokine production / extrinsic apoptotic signaling pathway / response to cytokine / acute-phase response / positive regulation of smooth muscle cell proliferation / cytokine-mediated signaling pathway / positive regulation of interleukin-6 production / Transcriptional regulation of granulopoiesis / defense response to Gram-negative bacterium / Interleukin-4 and Interleukin-13 signaling / Potential therapeutics for SARS / receptor complex / positive regulation of MAPK cascade / defense response to Gram-positive bacterium / apical plasma membrane / external side of plasma membrane / positive regulation of cell population proliferation / enzyme binding / protein homodimerization activity / extracellular space / extracellular region / plasma membrane 類似検索 - 分子機能 | ||||||
生物種 | ![]() | ||||||
手法 | 電子顕微鏡法 / 単粒子再構成法 / クライオ電子顕微鏡法 / 解像度: 3.3 Å | ||||||
![]() | She, J. / Chen, L. | ||||||
資金援助 | ![]()
| ||||||
![]() | ![]() タイトル: Structural insights into IL-6 signaling inhibition by therapeutic antibodies. 著者: Mingxing Wang / Long Chen / Jin He / Wenqiang Xia / Zihong Ye / Ji She / ![]() 要旨: Antibody inhibitors of the interleukin-6 (IL-6) signaling pathway, such as tocilizumab and sarilumab, have been used to treat rheumatoid arthritis, chimeric antigen receptor T cell-induced cytokine ...Antibody inhibitors of the interleukin-6 (IL-6) signaling pathway, such as tocilizumab and sarilumab, have been used to treat rheumatoid arthritis, chimeric antigen receptor T cell-induced cytokine storm, and severe COVID-19 pneumonia. Here, we solve the cryogenic electron microscopy structures of sarilumab and tocilizumab in complex with IL-6R to resolutions of 3.2 and 3.3 Å, respectively. These structures reveal that both tocilizumab and sarilumab bind to the D3 domain of IL-6R. The binding surfaces of the two antibodies largely overlap, but the detailed interactions are different. Functional studies of various mutants show results consistent with our structural analysis of the antibodies and IL-6R interactions. Structural comparisons with the IL-6/IL-6R/gp130 complex indicate that sarilumab and tocilizumab probably inhibit IL-6/IL-6R signaling by competing for the IL-6 binding site. In summary, this work reveals the antibody-blocking mechanism of the IL-6 signaling pathway and paves the way for future antibody discovery. | ||||||
履歴 |
|
-
構造の表示
構造ビューア | 分子: ![]() ![]() |
---|
-
ダウンロードとリンク
-
ダウンロード
PDBx/mmCIF形式 | ![]() | 118.2 KB | 表示 | ![]() |
---|---|---|---|---|
PDB形式 | ![]() | 84 KB | 表示 | ![]() |
PDBx/mmJSON形式 | ![]() | ツリー表示 | ![]() | |
その他 | ![]() |
-検証レポート
アーカイブディレクトリ | ![]() ![]() | HTTPS FTP |
---|
-関連構造データ
関連構造データ | ![]() 36003MC ![]() 8iowC M: このデータのモデリングに利用したマップデータ C: 同じ文献を引用 ( |
---|---|
類似構造データ | 類似検索 - 機能・相同性 ![]() |
-
リンク
-
集合体
登録構造単位 | ![]()
|
---|---|
1 |
|
-
要素
#1: 抗体 | 分子量: 24125.080 Da / 分子数: 1 / 由来タイプ: 組換発現 / 由来: (組換発現) ![]() ![]() |
---|---|
#2: 抗体 | 分子量: 23527.078 Da / 分子数: 1 / 由来タイプ: 組換発現 / 由来: (組換発現) ![]() ![]() |
#3: タンパク質 | 分子量: 40283.441 Da / 分子数: 1 / 由来タイプ: 組換発現 / 由来: (組換発現) ![]() ![]() |
#4: タンパク質・ペプチド | 分子量: 1148.355 Da / 分子数: 1 / 由来タイプ: 組換発現 / 由来: (組換発現) ![]() ![]() |
#5: 糖 | ChemComp-NAG / |
研究の焦点であるリガンドがあるか | N |
Has protein modification | Y |
-実験情報
-実験
実験 | 手法: 電子顕微鏡法 |
---|---|
EM実験 | 試料の集合状態: PARTICLE / 3次元再構成法: 単粒子再構成法 |
-
試料調製
構成要素 | 名称: the tocilizumab Fab/IL-6R complex / タイプ: COMPLEX / Entity ID: #1-#4 / 由来: RECOMBINANT |
---|---|
由来(天然) | 生物種: ![]() |
由来(組換発現) | 生物種: ![]() |
緩衝液 | pH: 8 |
試料 | 包埋: NO / シャドウイング: NO / 染色: NO / 凍結: YES |
急速凍結 | 凍結剤: ETHANE |
-
電子顕微鏡撮影
顕微鏡 | モデル: FEI TITAN |
---|---|
電子銃 | 電子線源: ![]() |
電子レンズ | モード: BRIGHT FIELD / 最大 デフォーカス(公称値): 2700 nm / 最小 デフォーカス(公称値): 1400 nm |
撮影 | 電子線照射量: 55 e/Å2 / フィルム・検出器のモデル: GATAN K3 (6k x 4k) |
-
解析
ソフトウェア | 名称: PHENIX / バージョン: 1.18.2_3874: / 分類: 精密化 | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CTF補正 | タイプ: NONE | ||||||||||||||||||||||||
3次元再構成 | 解像度: 3.3 Å / 解像度の算出法: FSC 0.143 CUT-OFF / 粒子像の数: 351599 / 対称性のタイプ: POINT | ||||||||||||||||||||||||
拘束条件 |
|